Tony Huge

Sugar Is Aging Your Body. Can the Damage Be Reversed? Tony Huge’s Video Guide

Table of Contents

Sugar welds itself to your proteins, and on the proteins that never turn over, that damage has been assumed permanent for 40 years. A July 2026 Nature Communications paper describes an engineered enzyme that stripped most of it off a 75-year-old human artery in a dish. Tony Huge breaks down the chemistry of glycation, what the enzyme actually did, the measurement discrepancy in the eye lens data, and then grades everything available today by whether it was measured in humans, animals, a dish, or nowhere.

Video: Sugar Is Aging Your Body. Can We Reverse the Damage? Published September 6, 2026. Watch on YouTube.

What the video covers

You cannot untoast toast

Tony starts with the kitchen. Bread goes in the toaster, sugar and protein meet heat, the bread browns. That is the Maillard reaction, the reason toast, steak, and beer taste the way they do. The same reaction runs inside the body at 37 degrees, slowly, for a lifetime. Sugar in the blood bumps into protein in tissue and sticks. It only needs time, temperature, and glucose. The sticky end products are advanced glycation end products, AGEs, and the most abundant one in aging human tissue is carboxymethyllysine, CML: a lysine residue with a sugar fragment welded to its side chain.

Why does that matter? Protein turnover. On a protein the body replaces every few days, glycation is irrelevant. But Tony cites turnover measurements that surprise people: skin collagen has a half-life of roughly 15 years, cartilage collagen 117 years, and the crystallin proteins of the eye lens date, by carbon dating, to around birth with almost no replacement after. On those proteins the damage never washes out. Every year of blood sugar you have ever had is still written into your lenses.

CML is not inert while it sits there. It fits a receptor on the cell surface called RAGE, and binding switches on an inflammatory program: chronic low-grade inflammation, oxidative stress, stiffer tissue. Stiff arteries mean blood pressure, stiff lens proteins mean cataracts, stiff collagen means skin that does not bounce back. The body has an upstream defense, the glyoxalase system, that mops up reactive sugar fragments before they weld on. Once the weld is made, nothing in human biology removes it. Hence the analogy: you cannot untoast toast.

What the enzyme did, and what it did not

Tony cites the paper: Nature Communications, July 2026, from Revel Pharmaceuticals, Calico Life Sciences, and the University of Colorado, funded by the National Institute on Aging, with the patent filed by Revel. He flags the incentive for bias up front and then takes the data seriously. The team started with a bacterial glycine oxidase that has no interest in collagen, ran directed evolution across over 500 million variants, and ended 15 amino acid substitutions and one deletion away from the start. They called it CMLase, and it does what the parent enzyme could not: find a lysine with a sugar fragment welded on, oxidize the weld off, and leave normal working lysine behind. Not a patch, not a replacement, the original amino acid restored.

On purified proteins, CML dropped between 52% (albumin) and 97% (collagen). The collagen number is the one that matters because collagen does not turn over. Of 33 damaged lysines on that protein, 30 got cleaner, seven by more than 90%, and three did not move because they sit buried inside folds the enzyme cannot reach. Selectivity held: a related lesion on arginine and every undamaged amino acid were left alone, which matters because an enzyme that chews healthy protein would be poison.

“You’re looking at 50 years of accumulated chemical damage, and most of it came off.”

Tony Huge, 09:20

On tissue: over 70% of CML came out of an artery from a 75-year-old donor, where arteries from 20 to 25-year-olds had essentially no CML staining to begin with. Over 55% came out of aged skin across outer and deep layers, and the post-treatment level was lower than skin from a 31-year-old. Then the eye lens, where the same tissue measured two ways gave 78% by antibody and 45% by mass spectrometry. Neither is a lie: the antibody can be blocked or confused by whatever is nearby and reads generously, while the mass spectrometer counts molecules and is stricter. Either way, he says, the number is impressive.

Four rungs of evidence

With an approved drug ten years away at best, Tony grades what is available now by where it has been measured: humans, animals, a dish, or nowhere. His first move is prevention: HbA1c is cheap and measures the average glucose that drives new glycation. Then he goes down his own list without sparing his favorites.

GHK-Cu does neutralize reactive molecules, but the two it is proven against, 4-HNE and acrolein, are not what makes CML; glyoxal is, and there are no GHK-glyoxal studies. The arrow from GHK to CML, he says, was drawn by marketing, and the number of studies linking GHK to RAGE is zero. He still likes it for skin and collagen, through a different pathway.

Glutathione is a genuine cofactor for the glyoxalase system, but the enzyme, glyoxalase 1, is the bottleneck, not the raw material. The number of human trials showing glutathione supplementation lowers AGEs is zero. But someone did run the right trial with a different tool: 29 overweight adults, eight weeks, randomized, placebo-controlled crossover, given resveratrol and hesperetin at doses that induce glyoxalase 1. The result was more enzyme, less circulating methylglyoxal, better glucose handling, and better vascular function. It is the only thing on the list that reaches the human rung for this pathway, and it works by building machines rather than delivering raw material.

BPC-157 has zero randomized human trials and extensive rat data; Tony reports it reduces inflammation in his body noticeably, which addresses a downstream symptom of glycation rather than glycation itself. 5-amino-1MQ rests on nine mice per group for 11 days; he takes it for NAD and fat loss, not glycation. Alagebrium, the classic cross-link breaker, works on different chemistry than CML, reached clinical trials, then failed its primary endpoints with a clean safety profile. Rosmarinic acid matches it in vitro. A multi-compound formula built around nicotinamide, alpha-lipoic acid, benfotiamine, pyridoxamine, and piperine lowered methylglyoxal and arterial stiffness in old mice, though as separate groups compared at the finish line, and Tony notes the lab behind it founded the company selling it.

Carnosine is the strongest oral compound on his list. Tony cites a randomized trial in type 2 diabetics at 1 g a day for 12 weeks that dropped plasma CML by 92 ng/mL along with fasting glucose, HbA1c, triglycerides, and TNF-alpha. It traps methylglyoxal, glyoxal, and acrolein, and serum carnosinase limits plasma levels, which is why higher doses or zinc-carnosine forms are commonly used.

Upstream of all of it

Glycation is driven by how high glucose runs and for how long. Tony’s foundation is therefore glucose disposal, and he describes the product he helped design, Slin pills, through two of its 11 ingredients. Kaempferol moves GLUT4, the glucose transporter, to the muscle surface at 10 picomolar without touching the insulin receptor, and a 9 mg oral dose delivers roughly 100 times that concentration to plasma. Myricetin raises GLUT4 expression in muscle and lowers phosphorylase activity so the muscle holds glycogen. One opens the door faster, the other builds more doors, and the aim is glucose into muscle instead of fat.

His own numbers: 20 years of overeating carbohydrate for mass with fasting glucose at 97 to 99, never diagnosed as anything, but 20 years of sugar looking for a lysine. Since starting the product his fasting glucose has run 82 to 92 even on high carbohydrate, a change he says sounds trivial until you compound it over years.

Cheat Sheet Pivot

What Tony reported for his own glycation protocol, and what the cited trials used.

  • Foundation: keep blood glucose low as often as possible, tracked by HbA1c, using Slin pills as the base of his stack.
  • The one human-rung intervention for the glyoxalase pathway used resveratrol plus hesperetin over eight weeks in 29 adults.
  • The carnosine trial used 1 g a day for 12 weeks; Tony notes 1 to 2 g a day or zinc-carnosine forms are what people commonly use because of carnosinase.
  • He keeps GHK-Cu, BPC-157, and 5-amino-1MQ in his stack for other reasons, acknowledging none has been shown to remove CML.
  • He is waiting on CMLase and estimates FDA approval at ten years or more.

Every compound in this section is indexed in the Miracle Molecules Cheat Sheet. For the B1 derivative in the multi-compound formula and its own anti-glycation evidence, read Benfotiamine: The Fat-Soluble B1 That Stops Glycation in Its Tracks. For what GHK-Cu does do, see GHK-Cu Peptide for Skin, Hair, and Anti-Aging.

Where the evidence stops

Everything in the CMLase paper happened in a dish. Tony lists the open questions himself: delivery to every tissue surface, whether removing CML makes tissue mechanically younger, whether it reduces RAGE inflammation, whether the immune system attacks a bacterial protein, and the fact that the 75-year-old and the 31-year-old are two different people rather than one measured twice. Most of the supplement list sits on the animal or dish rung, and he says which is which.

Keep going

For the NNMT inhibitor Tony mentioned keeping in his stack for other reasons, read 5-Amino-1MQ: The NNMT Inhibitor That Reprograms Aging Fat Cells. Companion articles reach the tonyhuge.is email list first, and the longevity archive is at tonyhuge.is.

Popular Category